Cargando…

TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas

Metabolic rewiring is a mechanism of adaptation to unfavorable environmental conditions and tumor progression. TRAP1 is an HSP90 molecular chaperone upregulated in human colorectal carcinomas (CRCs) and responsible for downregulation of oxidative phosphorylation (OXPHOS) and adaptation to metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales: Maddalena, Francesca, Condelli, Valentina, Matassa, Danilo Swann, Pacelli, Consiglia, Scrima, Rosella, Lettini, Giacomo, Li Bergolis, Valeria, Pietrafesa, Michele, Crispo, Fabiana, Piscazzi, Annamaria, Storto, Giovanni, Capitanio, Nazzareno, Esposito, Franca, Landriscina, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718945/
https://www.ncbi.nlm.nih.gov/pubmed/33025742
http://dx.doi.org/10.1002/1878-0261.12814
_version_ 1783619591151288320
author Maddalena, Francesca
Condelli, Valentina
Matassa, Danilo Swann
Pacelli, Consiglia
Scrima, Rosella
Lettini, Giacomo
Li Bergolis, Valeria
Pietrafesa, Michele
Crispo, Fabiana
Piscazzi, Annamaria
Storto, Giovanni
Capitanio, Nazzareno
Esposito, Franca
Landriscina, Matteo
author_facet Maddalena, Francesca
Condelli, Valentina
Matassa, Danilo Swann
Pacelli, Consiglia
Scrima, Rosella
Lettini, Giacomo
Li Bergolis, Valeria
Pietrafesa, Michele
Crispo, Fabiana
Piscazzi, Annamaria
Storto, Giovanni
Capitanio, Nazzareno
Esposito, Franca
Landriscina, Matteo
author_sort Maddalena, Francesca
collection PubMed
description Metabolic rewiring is a mechanism of adaptation to unfavorable environmental conditions and tumor progression. TRAP1 is an HSP90 molecular chaperone upregulated in human colorectal carcinomas (CRCs) and responsible for downregulation of oxidative phosphorylation (OXPHOS) and adaptation to metabolic stress. The mechanism by which TRAP1 regulates glycolytic metabolism and the relevance of this regulation in resistance to EGFR inhibitors were investigated in patient‐derived CRC spheres, human CRC cells, samples, and patients. A linear correlation was observed between TRAP1 levels and (18)F‐fluoro‐2‐deoxy‐glucose ((18)F‐FDG) uptake upon PET scan or GLUT1 expression in human CRCs. Consistently, TRAP1 enhances GLUT1 expression, glucose uptake, and lactate production and downregulates OXPHOS in CRC patient‐derived spheroids and cell lines. Mechanistically, TRAP1 maximizes lactate production to balance low OXPHOS through the regulation of the glycolytic enzyme phosphofructokinase‐1 (PFK1); this depends on the interaction between TRAP1 and PFK1, which favors PFK1 glycolytic activity and prevents its ubiquitination/degradation. By contrast, TRAP1/PFK1 interaction is lost in conditions of enhanced OXPHOS, which results in loss of TRAP1 regulation of PFK1 activity and lactate production. Notably, TRAP1 regulation of glycolysis is involved in resistance of RAS‐wild‐type CRCs to EGFR monoclonals. Indeed, either TRAP1 upregulation or high glycolytic metabolism impairs cetuximab activity in vitro, whereas TRAP1 targeting and/or inhibition of glycolytic pathway enhances cell response to cetuximab. Finally, a linear correlation between (18)F‐FDG PET uptake and poor response to cetuximab in first‐line therapy in human metastatic CRCs was observed. These results suggest that TRAP1 is a key determinant of CRC metabolic rewiring and favors resistance to EGFR inhibitors through regulation of glycolytic metabolism.
format Online
Article
Text
id pubmed-7718945
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77189452020-12-11 TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas Maddalena, Francesca Condelli, Valentina Matassa, Danilo Swann Pacelli, Consiglia Scrima, Rosella Lettini, Giacomo Li Bergolis, Valeria Pietrafesa, Michele Crispo, Fabiana Piscazzi, Annamaria Storto, Giovanni Capitanio, Nazzareno Esposito, Franca Landriscina, Matteo Mol Oncol Research Articles Metabolic rewiring is a mechanism of adaptation to unfavorable environmental conditions and tumor progression. TRAP1 is an HSP90 molecular chaperone upregulated in human colorectal carcinomas (CRCs) and responsible for downregulation of oxidative phosphorylation (OXPHOS) and adaptation to metabolic stress. The mechanism by which TRAP1 regulates glycolytic metabolism and the relevance of this regulation in resistance to EGFR inhibitors were investigated in patient‐derived CRC spheres, human CRC cells, samples, and patients. A linear correlation was observed between TRAP1 levels and (18)F‐fluoro‐2‐deoxy‐glucose ((18)F‐FDG) uptake upon PET scan or GLUT1 expression in human CRCs. Consistently, TRAP1 enhances GLUT1 expression, glucose uptake, and lactate production and downregulates OXPHOS in CRC patient‐derived spheroids and cell lines. Mechanistically, TRAP1 maximizes lactate production to balance low OXPHOS through the regulation of the glycolytic enzyme phosphofructokinase‐1 (PFK1); this depends on the interaction between TRAP1 and PFK1, which favors PFK1 glycolytic activity and prevents its ubiquitination/degradation. By contrast, TRAP1/PFK1 interaction is lost in conditions of enhanced OXPHOS, which results in loss of TRAP1 regulation of PFK1 activity and lactate production. Notably, TRAP1 regulation of glycolysis is involved in resistance of RAS‐wild‐type CRCs to EGFR monoclonals. Indeed, either TRAP1 upregulation or high glycolytic metabolism impairs cetuximab activity in vitro, whereas TRAP1 targeting and/or inhibition of glycolytic pathway enhances cell response to cetuximab. Finally, a linear correlation between (18)F‐FDG PET uptake and poor response to cetuximab in first‐line therapy in human metastatic CRCs was observed. These results suggest that TRAP1 is a key determinant of CRC metabolic rewiring and favors resistance to EGFR inhibitors through regulation of glycolytic metabolism. John Wiley and Sons Inc. 2020-10-30 2020-12 /pmc/articles/PMC7718945/ /pubmed/33025742 http://dx.doi.org/10.1002/1878-0261.12814 Text en © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Maddalena, Francesca
Condelli, Valentina
Matassa, Danilo Swann
Pacelli, Consiglia
Scrima, Rosella
Lettini, Giacomo
Li Bergolis, Valeria
Pietrafesa, Michele
Crispo, Fabiana
Piscazzi, Annamaria
Storto, Giovanni
Capitanio, Nazzareno
Esposito, Franca
Landriscina, Matteo
TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas
title TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas
title_full TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas
title_fullStr TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas
title_full_unstemmed TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas
title_short TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas
title_sort trap1 enhances warburg metabolism through modulation of pfk1 expression/activity and favors resistance to egfr inhibitors in human colorectal carcinomas
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718945/
https://www.ncbi.nlm.nih.gov/pubmed/33025742
http://dx.doi.org/10.1002/1878-0261.12814
work_keys_str_mv AT maddalenafrancesca trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT condellivalentina trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT matassadaniloswann trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT pacelliconsiglia trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT scrimarosella trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT lettinigiacomo trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT libergolisvaleria trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT pietrafesamichele trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT crispofabiana trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT piscazziannamaria trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT stortogiovanni trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT capitanionazzareno trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT espositofranca trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas
AT landriscinamatteo trap1enhanceswarburgmetabolismthroughmodulationofpfk1expressionactivityandfavorsresistancetoegfrinhibitorsinhumancolorectalcarcinomas